PROFILEing idiopathic pulmonary fibrosis: Rethinking biomarker discovery

European Respiratory Review

Volumn 22, Issue 128, 2013, Pages 148-152

  Maher, Toby M ^a,b,c  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Biomarkers; Clinical management; Idiopathic pulmonary fibrosis; Pharmacological treatment; PROFILE study; Prognosis

Indexed keywords

ANTIFIBROTIC AGENT; INTERLEUKIN 13 ANTIBODY; PIRFENIDONE; TRANSCRIPTION FACTOR RUNX2;

ASTHMA; DISEASE COURSE; DRUG RESPONSE; FIBROSING ALVEOLITIS; GOLD STANDARD; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; LUNG BIOPSY; PATHOGENESIS; PHENOTYPE; PREDICTION; PROGNOSIS; REVIEW; SURVIVAL RATE;

BIOMARKERS; CLINICAL MANAGEMENT; IDIOPATHIC PULMONARY FIBROSIS; PHARMACOLOGICAL TREATMENT; PROFILE STUDY; PROGNOSIS;

BIOLOGICAL MARKERS; DISEASE PROGRESSION; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROTEINS; PROTEOMICS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84878454973     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/09059180.00000913     Document Type: Review

References (27)

1. Maher TM, Wells AU, Laurent GJ. Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms? Eur Respir J 2007; 30: 835-839.
2. Navaratnam V, Fleming KM, West J, et al. The rising incidence of idiopathic pulmonary fibrosis in the UK. Thorax 2011; 66: 462-467.
3. Raghu G, Weycker D, Edelsberg J, et al. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006; 174: 810-816.
4. Demedts M, Wells AU, Anto JM, et al. Interstitial lung diseases: an epidemiological overview. Eur Respir J 2001; 18: Suppl. 32, 2s-16s.
5. American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society. International multi-disciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2002; 165: 277-304.
6. Flaherty KR, King TE Jr, Raghu G, et al. Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis? Am J Respir Crit Care Med 2004; 170: 904-910.
7. Nicholson AG, Addis BJ, Bharucha H, et al. Inter-observer variation between pathologists in diffuse parenchymal lung disease. Thorax 2004; 59: 500-505.
8. Kinder BW, Collard HR, Koth L, et al. Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease? Am J Respir Crit Care Med 2007; 176: 691-697.
9. Corte TJ, Copley SJ, Desai SR, et al. Significance of connective tissue disease features in idiopathic interstitial pneumonia. Eur Respir J 2012; 39: 661-668.
10. Martinez FJ, Safrin S, Weycker D, et al. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med 2005; 142: 963-967.
11. Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 183: 431-440.
12. Collard HR, Moore BB, Flaherty KR, et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2007; 176: 636-643.
13. Maher TM. Idiopathic pulmonary fibrosis: pathobiology of novel approaches to treatment. Clin Chest Med 2012; 33: 69-83.
14. Raghu G, Brown KK, Bradford WZ, et al. A placebo-controlled trial of interferonc-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 2004; 350: 125-133.
15. Maher TM. Pirfenidone in idiopathic pulmonary fibrosis. Drugs Today (Barc) 2010; 46: 473-482.
16. King TE Jr, Brown KK, Raghu G, et al. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 184: 92-99.
17. Demedts M, Behr J, Buhl R, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005; 353: 2229-2242.
18. Raghu G, Collard HR, Anstrom KJ, et al. Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med 2012; 185: 1044-1048.
19. Vancheri C, Du Bois RM. A progression-free end-point for idiopathic pulmonary fibrosis trials: lessons from cancer. Eur Respir J 2013; 41: 262-269.
20. Du Bois RM, Nathan SD, Richeldi L, et al. Idiopathic pulmonary fibrosis: lung function is a clinically meaningful endpoint for phase III trials. Am J Respir Crit Care Med 2012; 186: 712-715.
21. Wells AU, Behr J, Costabel U, et al. Hot of the breath: mortality as a primary end-point in IPF treatment trials: the best is the enemy of the good. Thorax 2012; 67: 938-940.
22. Patel JP, Gonen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 2012; 366: 1079-1089.
23. Corren J, Mansfield LE, Pertseva T, et al. Efficacy and safety of fluticasone/formoterol combination therapy in patients with moderate-to-severe asthma. Resp Med 2013; 107: 180-195.
24. Rosas IO, Richards TJ, Konishi K, et al. MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. PLoS Med 2008; 5: e93.
25. Selman M, Carrillo G, Estrada A, et al. Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern. PLoS One 2007; 2: e482.
26. Selman M, Pardo A, Barrera L, et al. Gene expression profiles distinguish idiopathic pulmonary fibrosis from hypersensitivity pneumonitis. Am J Respir Crit Care Med 2006; 173: 188-198.
27. Yang IV, Luna LG, Cotter J, et al. The peripheral blood transcriptome identifies the presence and extent of disease in idiopathic pulmonary fibrosis. PLoS One 2012; 7: e37708.